Oct 19, 2020
Oncolytics Biotech® Appoints Richard Vile, Ph.D., to its Scientific Advisory Board
Jul 29, 2020
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights
May 29, 2020
Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual Meeting
May 26, 2020
Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting
May 08, 2020
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
Apr 30, 2020
Oncolytics Biotech® Announces Changes to Annual General Meeting
Jan 13, 2020
Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma
Dec 04, 2017
Oncolytics Biotech® to Present at the Oncolytic Virotherapy Summit
Sep 19, 2017
Oncolytics Biotech® to Present at the Phacilitate Immuno-Oncology Frontiers Conference
Sep 18, 2017
Oncolytics Biotech® Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN® in Metastatic Breast Cancer
Sep 14, 2017
Oncolytics Biotech® Announces First Patient Treated in MUK eleven Study
Aug 03, 2017
Oncolytics Biotech® Inc. Announces 2017 Second Quarter Results
Aug 01, 2017
Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference
Jun 27, 2017
Oncolytics Biotech® Inc. Opens U.S. Based Office in San Diego